https://scholars.lib.ntu.edu.tw/handle/123456789/604454
Title: | Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study | Authors: | Krop, Ian E Im, Seock-Ah Barrios, Carlos Bonnefoi, Hervé Gralow, Julie Toi, Masakazu Ellis, Paul A Gianni, Luca Swain, Sandra M Im, Young-Hyuck De Laurentiis, Michelino Nowecki, Zbigniew CHIUN-SHENG HUANG Fehrenbacher, Louis Ito, Yoshinori Shah, Jigna Boulet, Thomas Liu, Haiying Macharia, Harrison Trask, Peter Song, Chunyan Winer, Eric P Harbeck, Nadia |
Issue Date: | 2022 | Journal Volume: | 40 | Journal Issue: | 5 | Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Abstract: | We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/604454 | ISSN: | 0732183X | DOI: | 10.1200/JCO.21.00896 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.